Search Results

Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases

Authors: Boonen, S.; Kay, R.; Cooper, C.; Haentjens, P.; Vanderschueren, D.; Callewaert, F.; Milisen, K.; Ferrari, S.

Source: International Journal of Clinical Practice, Volume 63, Number 12, December 2009 , pp. 1792-1804(13)

Publisher: Blackwell Publishing

Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression

Authors: Binkley, N.; Silverman, S.; Simonelli, C.; Santiago, N.; Kohles, J.; Dasic, G.; Sunyecz, J.

Source: Osteoporosis International, Volume 20, Number 9, September 2009 , pp. 1595-1601(7)

Publisher: Springer

Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer

Authors: HERAS, P.; KRITIKOS, K.; HATZOPOULOS, A.; GEORGOPOULOU, A.-P.

Source: European Journal of Cancer Care, Volume 18, Number 6, November 2009 , pp. 653-656(4)

Publisher: Blackwell Publishing

Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review

Authors: Diel, Ingo; Weide, Rudolf; Köppler, Hubert; Antràs, Lucia; Smith, Michael; Green, Jesse; Wintfeld, Neil; Neary, Maureen; Duh, Mei

Source: Supportive Care in Cancer, Volume 17, Number 6, June 2009 , pp. 719-725(7)

Publisher: Springer

Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients

Authors: Kyrgidis, Athanassios; Triaridis, Stefanos; Vahtsevanos, Kostantinos; Antoniades, Kostantinos

Source: Expert Review of Anticancer Therapy, Volume 9, Number 8, August 2009 , pp. 1125-1134(10)

Publisher: Expert Reviews

Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women

Author: THE BonAdASIA STUDY GROUP,

Source: International Journal of Rheumatic Diseases, Volume 12, Number 3, September 2009 , pp. 216-224(9)

Publisher: Blackwell Publishing

Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?

Authors: Morgan, Claire; Wagstaff, John

Source: Acta Oncologica, Volume 48, Number 6, August 2009 , pp. 882-889(8)

Publisher: Informa Healthcare

Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy

Authors: Amling, Michael; Kurth, Andreas

Source: Women's Health, Volume 5, Number 5, September 2009 , pp. 467-473(7)

Publisher: Future Medicine

Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates: A Case Series from a Swiss University Hospital

Authors: Ing-Lorenzini, Kuntheavy; Desmeules, Jules; Plachta, Olivier; Suva, Domizio; Dayer, Pierre; Peter, Robin

Source: Drug Safety, Volume 32, Number 9, 1 September 2009 , pp. 775-785(11)

Publisher: Adis International

Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy

Authors: Gold, Deborah T.; Trinh, Haian; Safi, Wael

Source: Current Medical Research and Opinion, Volume 25, Number 8, August 2009 , pp. 1831-1839(9)

Publisher: Informa Healthcare

Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies

Authors: Jansen, Jeroen P.; Bergman, Gert J. D.; Huels, Jasper; Olson, Melvin

Source: Current Medical Research and Opinion, Volume 25, Number 8, August 2009 , pp. 1861-1868(8)

Publisher: Informa Healthcare

Evaluating the Antifracture Efficacy of Bisphosphonates

Authors: Pazianas, Michael; Epstein, Solomon; Zaidi, Mone

Source: Reviews on Recent Clinical Trials, Volume 4, Number 2, May 2009 , pp. 122-130(9)

Publisher: Bentham Science Publishers

Regional migratory osteoporosis in a patient with ankylosing spondylitis

Authors: Straten, V. H. H. P.; Franssen, M. J. A. M.; den Broeder, A. A.; Obradov, M.; van den Hoogen, F. H. J.

Source: Scandinavian Journal of Rheumatology, Volume 38, Number 1, 2009 , pp. 63-65(3)

Publisher: Informa Healthcare

Treatment options for breast cancer and bone metastases

Author: Pecherstorfer, Martin

Source: Women's Health, Volume 5, Number 2, March 2009 , pp. 149-163(15)

Publisher: Future Medicine

The Management of Metastatic Bone Disease with the Combination of Bisphosphonates and Radiotherapy: From Theory to Clinical Practice

Authors: Vassiliou, V.; Kardamakis, D.

Source: Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry, Volume 9, Number 3, March 2009 , pp. 326-335(10)

Publisher: Bentham Science Publishers

Ibandronate: A Review of its Use in the Management of Postmenopausal Osteoporosis

Authors: Frampton, James E.; Perry, Caroline M.

Source: Drugs, Volume 68, Number 18, 2008 , pp. 2683-2707(25)

Publisher: Adis International

Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update

Author: Pecherstorfer, Martin

Source: Expert Opinion on Pharmacotherapy, Volume 9, Number 17, December 2008 , pp. 3111-3119(9)

Publisher: Informa Healthcare

Ibandronate: is there an effect on nonvertebral fractures?

Authors: Kastelan, Darko; Korsic, Mirko; Vlak, Tonko

Source: Clinical Rheumatology, Volume 27, Number 10, October 2008 , pp. 1313-1315(3)

Publisher: Springer

Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance

Authors: Boonen, S.; Vanderschueren, D.; Venken, K.; Milisen, K.; Delforge, M.; Haentjens, P.

Source: Journal of Internal Medicine, Volume 264, Number 4, October 2008 , pp. 315-332(18)

Publisher: Blackwell Publishing

Oral nitrogen-containing bisphosphonates: a systematic review of randomized clinical trials and vertebral fractures

Authors: Bianchi, Gerolamo; Sambrook, Philip

Source: Current Medical Research and Opinion, Volume 24, Number 9, September 2008 , pp. 2669-2677(9)

Publisher: Informa Healthcare